Recombinant Human Epiregulin Protein, Active

Product Overview Product Name Recombinant Human Epiregulin Protein Target Symbol EREG Alternative Names EREG, Proepiregulin Accession Number O14944 Expression System E. coli. Molecular Weight 5.7 kDa (predicted) Sequence Val60-Leu108, with an N-terminal Met Purity Determined by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining Activity Determined by in-house activity assay Formulation Lyophilized from sterile PBS with Trehalose, pH 7.4 Endotoxin Level Available Upon Request Shipping Shipped at ambient temperature. Stability & Storage 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles. Reconstitution Reconstitute at 100 ug/mL in sterile PBS. Target Function Epiregulin is a widely expressed growth factor involved in cell growth, proliferation, differentiation, and tissue repair. Epiregulin is expressed by peripheral blood macrophages and normal keratinocytes in response to tissue damage which promotes inflammation, angiogenesis and fibroblast-mediated wound healing. Epiregulin is also produced in the placenta, uterus and during ovarian follicle formation. Epiregulin promotes the proliferation of smooth muscle cells and hepatocytes. Signaling by Epiregulin occurs with the binding of EGFR (ErbB1) or ErbB4. Tissue Specificity Epiregulin expression has been identified in skin, gastrointestinal tract, respiratory tract, ovaries, uterus, placenta, liver, brain, kidney, pancreas, and adipose tissues. Cellular Localization Membrane-bound and cleaved soluble protein forms Involvement In Disease Dysregulation of Epiregulin is associated with atherosclerosis, cardiac hypertrophy, polycystic ovary syndrome (PCOS), psoriasis, atopic dermatitis, inflammatory bowel disease (IBD), rheumatoid arthritis, and various cancers (breast cancer, colorectal cancer, lung cancer, ovarian cancer) due to tumor growth and metastasis.